Liz has spent over 11 years working with academic, biotech and contract development and manufacturing organizations, focusing on the manufacturing of allogeneic and autologous cell therapy products.
Liz joined Dark Horse Consulting as Senior Consultant in September of 2021. Liz's consistent emphasis is to get clients to a place of efficiency and operational excellence; she supports a range of DHC clients across developmental stages and modalities for whom those goals align.
Her career began at the University of Pennsylvania, Clinical Vaccine Production Facility with a primary focus on early phases allogeneic and autologous cell therapy production. While at Penn, Liz expanded her working knowledge of cGMP cell therapy production and early phase regulatory submission and management.
In 2016, Liz joined Wuxi Advanced Therapies where she managed multiple manufacturing facilities: most recently, an FDA and EU compliant commercial cell therapy manufacturing facility. Liz developed a plethora of experience on capacity and for ecast planning, budget and strategy plans for labor utilization, and internal and external technology transfers for both early and late/commercial phase cell therapy products. Liz has a proven track record of establishing and partnering within a cross-functional setting to continually drive progress and quality production of cell therapy products. Liz was extensively involved in building out systems within the organization, especially related to supply chain.
In 2020, Liz joined WindMIL Therapeutics, leading CMO activities and deliverables in support of the company’s core technologies and pipeline products. She drove activities to establish supply chain capabilities and increase the company’s manufacturing footprint.